Corporate Banner
Satellite Banner
Spectroscopy
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Verisante Technology, Inc. Announces Exclusive Distribution Agreement with BO-Pharma BV

Published: Thursday, September 20, 2012
Last Updated: Thursday, September 20, 2012
Bookmark and Share
Company to Attend 21st Congress of the European Academy of Dermatology in Prague, Czech Republic.

Verisante Technology, Inc. announced that the Company has entered into an exclusive agreement with BO-Pharma BV to distribute Verisante Aura™ in Belgium, the Netherlands and Luxemburg ("Benelux").

"BO-Pharma is the largest independent distributor of medical devices in the Benelux region," said Thomas Braun, President & CEO of Verisante. "With the Benelux market outselling the UK and Germany in some dermatological and skin care devices, our partnership with BO-Pharma provides us a strong foothold in this important region. BO-Pharma will not only distribute Aura™, but can also support technical training and servicing in the region."

BO-Pharma and its affiliate, Bo-Esthetics, currently distribute medical devices for skin care treatments, in addition to other devices for use in dermatological practices for a variety of other medical applications. Bo-Esthetics is a leading dermatology distributor in Benelux, distributing the world's top dermatology brands. Aura™ is a natural addition to the Company's existing product line.

"Impressive clinical study results show that Aura™, through speed and accuracy, is a device that can revolutionize the way skin cancer is diagnosed," said Dr. Henk-Peter Oonk, CEO of BO-Pharma. "The Netherlands has historically been very quick to adopt new, disruptive medical technologies, and we are confident this trend will continue with Aura™."

Last year, Aura™ received the Conformite Europeenne (CE) Mark approval, which is recognized by all the 27 Member States of the EU, including Benelux, which has a total population of over 30 million people, and approximately 1,000 dermatologists serving the region. The CE Mark allows the Company to sell Aura™ in Europe, a $78 billion medical device market.

Verisante Aura™ is indicated for use for the evaluation of skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma and/or basal cell carcinoma when a medical professional chooses to obtain additional information to rule out one of the above conditions before making a final decision to biopsy. Aura™ is a non-invasive optical system that uses Raman spectroscopy to biochemically analyze the skin, providing immediate and accurate results. The device will help to automate the current process of diagnosis, allowing rapid scanning of the 20 to 40 skin lesions on at-risk individuals, improving patient outcomes and comfort.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Hunting the Missing Link Between Genetics and the Environment
The International Phenome Centre Network (IPCN) works to transform healthcare through phenomics - the dynamic interactions between our genes and our environment.
Chemical Snapshots Could Lead to Better Engineered Cartilage
Taking "chemical photographs" of the cartilage between joints and comparing it to engineered versions could lead to better implants, say researchers.
Identifying Functional Biomarkers of Traumatic Brain Injury
In this study, prefrontal hemodynamic biomarkers were identified that can distinguish traumatic brain injury patients from healthy subjects.
Peer Review is in Crisis, But Should be Fixed, Not Abolished
After the time to get the science done, peer review has become the slowest step in the process of sharing studies, and some scientists have had enough.
Identification of Individual Red Blood Cells by Raman Microspectroscopy
In this study, Raman Microspectroscopy was used to identify individual red blood cells.
The Power Of Orthogonality In Assessing The Stability Of Biopharmaceuticals
By utilizing orthogonal techniques, researchers can maximize the secure application of all analytical results generated.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Curcumin Shows Promise as Cancer Treatment
When delivered at the correct circadian phase, curcumin demonstrates sustained toxicity in cancer cells and should be considered for use in patient care.
Using the Linkam THMS600 Temperature Stage to Study Fluid Inclusions
The University of Lyon use the Linkam THMS600 temperature stage for the study of Brillouin spectroscopy of fluid inclusions.
Guided Needles Hit the Mark
New sensor could help anesthesiologists place needles for epidurals and other medical procedures.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!